| Jul 14 |
Regeneron Pharmaceuticals (NASDAQ:REGN) stock performs better than its underlying earnings growth over last five years
|
| Jul 11 |
Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
|
| Jul 8 |
3 No-Brainer Stocks to Buy in July
|
| Jul 5 |
Swing Trading Regeneron Stock Shows How To Bob And Weave
|
| Jul 5 |
Dupixent “addresses current gap” in COPD biologics landscape
|
| Jul 4 |
7 High Priced Stocks That Would Benefit From a Stock Split
|
| Jul 3 |
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
|
| Jul 3 |
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
|
| Jul 3 |
Sanofi, Regeneron win EU label expansion for Dupixent in COPD
|
| Jul 3 |
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
|
